Future of polypill use for the prevention of cardiovascular disease and strokes

American Journal of Cardiology

Volumn 114, Issue 4, 2014, Pages 641-645

  Chrysant, Steven G ^a,b   Chrysant, George S ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b INTEGRIS BAPTIST MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; SIMVASTATIN; DRUG COMBINATION;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG USE; HUMAN; PILL; POLYPILL; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; DRUG COMBINATION; HEALTH; INCIDENCE; PROCEDURES; RISK FACTOR; STROKE; SURVIVAL RATE; TRENDS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; GLOBAL HEALTH; HUMANS; INCIDENCE; PRIMARY PREVENTION; RISK FACTORS; STROKE; SURVIVAL RATE;

EID: 84905595193     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.05.049     Document Type: Review

References (29)

1. World Health Organization Statistics 2013. Cardiovascular diseases. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed on February 27, 2014.
2. C.J.L. Murray, and A.D. Lopez Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study Lancet 349 1997 1498 1504
3. E.A. Ford, U.A. Ajani, J.B. Croft, J.A. Gritchley, D.R. Labarthe, T.E. Kottke, W.H. Giles, and S. Capewell Explaining the decline in coronary mortality in the United States between 1980 and 2000 N Engl J Med 356 2007 2388 2398
4. R.V. Luepker, and A.K. Berger Is the acute myocardial infarction disappearing? Circulation 121 2010 1280 1282
5. F. Levi, L. Chatenoud, P. Bertuccio, F. Lucchini, E. Negri, and C. La Vecchia Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update Eur J Cardivasc Prev Rehabil 16 2009 333 350
6. D.M. Lloyd-Jones, E.P. Leip, M.G. Larson, R.B. D'Agustino, A. Beiser, P.W.F. Wilson, P.A. Wolf, and D. Levy Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 113 2006 791 798
7. N.J. Wald, and M.R. Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419
8. M.R. Law, N.J. Wald, and A. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423 1427
9. M.R. Law, N.J. Wald, and S.G. Thompson By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? BMJ 308 1994 367 372
10. Homocysteine Lowering Trialists Collaboration Lowering blood homocysteine with folic acid based supplements. Meta-analysis of randomized trials BMJ 316 1998 894 898
11. M.R. Law, N.J. Wald, J.K. Morris, and R. Jordan Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials BMJ 326 2003 1427 1431
12. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomized trials on antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients BMJ 324 2002 71 86
13. S. Yusuf, P. Pais, R. Afzal, D. Xavier, K. Teo, J. Eikelboom, A. Sigamani, V. Mohan, R. Gupta, and N. Thomas Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet 373 2009 1341 1351
14. F. Malekzadeh, T. Marshall, A. Pourshams, M. Garrawi, A. Aslani, A. Nateghi, M. Rasteganah, M. Khoshnia, S. Semnani, R. Salahi, G.N. Thomas, B. Larijani, K.K. Cheng, and R. Malekzadeh A pilot double-blind randomized placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors Int J Clin Pract 64 2010 1220 1227
15. A. Rodgers, A. Patel, O. Berwanger, M. Bots, R. Grimm, D.E. Grobbee, R. Jackson, B. Neal, J. Neaton, N. Poulter, N. Rafter, P.K. Raju, S. Reddy, S. Thom, S. Vander Hoorn, R. Webster PILL Collaboration Group An international randomized placebo-controlled trial of four component combination pill ("polypill") in people with raised cardiovascular risk PLoS One 6 2011 e19857
16. D.S. Wald, J.K. Morris, and N.J. Wald Randomized crossover trial in people aged 50 and over PLoS One 7 2012 e41297
17. M.S. Bittencourt, M.J. Blaha, R. Blankstein, M. Budoff, J.D. Vargas, R.S. Blumenthal, A.S. Agatston, and K. Nasir Polypill therapy, subclinical atherosclerosis, and cardiovascular events - implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis J Am Coll Cardiol 63 2014 434 443
18. P. Greenland, M.S. LaBree, S.P. Azen, T.M. Doherty, and R.G. Detrano Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals JAMA 291 2004 210 215
19. K. Kotseva, D. Wood, G. De Backer, D. De Backer, K. Pyorala, U. Keil EUROASPIRE Study Group EUROASPIRE III: a survey on the lifestyle, risk factors, and use of cardioprotective drug therapies in coronary patients from 22 European countries Eur J Cardiovasc Prev Rehabil 16 2009 121 137
20. S. Mendis, D. Abegunde, S. Yusuf, S. Ebrahim, G. Shaper, H. Ghannem, and B. Shengelia WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE) Bull World Health Organ 83 2005 820 829
21. T.A. Gaziano, L.H. Opie, and M.C. Weinstein Cardiovascular disease prevention with multidrug regimen in the developing world: a cost-effectiveness analysis Lancet 368 2006 679 686
22. S. Mendis, K. Fukino, A. Cameron, R. Laing, A. Filipe Jr., O. Khatib, J. Leowski, and M. Ewen The availability and affordability of selected essential medicines for chronic diseases in six low-and-medium income countries Bull World Health Organ 85 2007 279 288
23. A. Patel, T. Shah, G. Shah, V. Jha, C. Ghosh, J. Desai, B. Khamar, and B.S. Chakraborty Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (Polycap): a five-arm phase I crossover trial in healthy volunteers Am J Cardiovasc Drugs 10 2010 95 105
24. P. Sutcliffe, M. Connock, T. Gurung, K. Freeman, S. Johnson, K. Ngianga-Bakwin, A. Grove, B. Gurung, S. Morrow, S. Stranges, and A. Clarke Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials PLoS One 8 2013 e81970
25. S.K. Virdee, S.M. Greenfield, K. Fletcher, R.J. McManus, F.D.R. Hobbs, and J. Mant Would primary care professionals prescribe a polypill to manage cardiovascular risk ? A qualitative interview study BMJ Open 3 2013 e002498
26. A.J. Viera, S.L. Sheridan, T. Edwards, E.Z. Soliman, R. Harris, and C.D. Furberg Acceptance of a polypill approach to prevent cardiovascular disease among a sample of US physicians Prev Med 52 2011 10 15
27. M.R. Law, H.C. Watt, and N.J. Wald The underlying risk of death after myocardial infarction in the absence of treatment Arch Intern Med 162 2002 2405 2410
28. W. Wijns, and D. Rusinaru "De-risking" risk reduction: should coronary artery calcium scoring be the gatekeeper to preventive pharmacotherapy with the polypill? J Am Coll Cardiol 63 2014 444 446
29. V. Raman, E.M. McWilliams, S.M. Holmberg, and K. Miles Economic analysis of the use of coronary calcium scoring as an alternative to stress ECG in the non-invasive diagnosis of coronary artery disease Eur Radiol 22 2012 579 587